David A. Rodriguez, M D
Specialist
- Medicare participating
At a glance
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 100
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
FL license ME0050087 -
Dermatology Physician
FL license ME0050087
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- The Derm Group LLP (32 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 100
- Services billed
- 487
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 263 | 103 |
| Destruction of precancer skin growth, 15 or more growths | 215 | 86 |
| Destruction of precancer skin growth, 2-14 growths | 110 | 14 |
| Biopsy of related skin growth, first growth | 55 | 41 |
| New patient office or other outpatient visit, 30-44 minutes | 48 | 48 |
| Established patient office or other outpatient visit, 30-39 minutes | 35 | 23 |
| Destruction of precancer skin growth, 1 growth | 30 | 14 |
| Destruction of skin growth, 1-14 growths | 20 | 14 |
| New patient office or other outpatient visit, 45-59 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ketoconazole Other prescribers in Miami, FL | 470 |
| Hydrocortisone Other prescribers in Miami, FL | 293 |
| Clobetasol Propionate Other prescribers in Miami, FL | 240 |
| Triamcinolone Acetonide Other prescribers in Miami, FL | 239 |
| Fluorouracil Other prescribers in Miami, FL | 187 |
| Mometasone Furoate Other prescribers in Miami, FL | 116 |
| Ciclopirox Other prescribers in Miami, FL | 112 |
| Clindamycin Phosphate Other prescribers in Miami, FL | 83 |
| Minoxidil Other prescribers in Miami, FL | 83 |
| Jublia (efinaconazole) | 77 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 74 payments worth $3,534 in total to this clinician.
| Leo Pharma Inc. | $438 |
|---|---|
| Janssen Biotech, Inc. | $437 |
| Amgen Inc. | $397 |
| UCB, Inc. | $330 |
| Lilly USA, LLC | $325 |
| Sun Pharmaceutical Industries Inc. | $279 |
| Journey Medical Corporation | $235 |
| E.r. Squibb & Sons, L.l.c. | $186 |
| Food and Beverage | $3,419 |
|---|---|
| Travel and Lodging | $115 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Dec 3, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $115 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 9 companies. The companies reported $1,081,343 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sanofi US Services Inc. · Active, not recruiting · NCT06407934 - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
Sanofi US Services Inc. · Completed · NCT06181435 - A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASC…
Amgen Inc. - A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
Incyte Corporation - A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Novartis Pharmaceuticals Corporation - Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE)
Janssen Research & Development, LLC - Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
Sanofi US Services Inc. · Active, not recruiting · NCT05492578 - Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
Sanofi Pasteur Inc. · Recruiting · NCT06316297 - A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis …
Amgen Inc. - Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
E.r. Squibb & Sons, L.l.c. · Completed · NCT04036435
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.